AI公司曦嘉医疗获数千万元天使轮融资，开发中国版斯坦福疗法抗抑郁

Core Viewpoint - NuraNavX, a brain science AI company, has recently completed a multi-million yuan angel round financing, primarily aimed at market promotion and further research of its AI brain connectomics products [1] Group 1: Company Overview - NuraNavX focuses on brain connectomics, analyzing the connections and networking of neurons to understand brain functions and mechanisms, which is crucial for understanding complex brain diseases [1][2] - The company has treated over 1,000 patients in domestic clinical settings using its AI-based individualized brain network mapping technology [1] Group 2: Technology and Applications - The company utilizes MRI data to divide each patient's brain into 379 unique regions and studies over 20 important brain functional networks through its proprietary SCA (Structural Connectome Atlas) technology [2] - SCA technology employs machine learning to extract structural features of neural fiber bundles, creating personalized brain network models for surgical planning and treatment of central nervous system diseases [2][3] Group 3: Surgical Applications - Nura Surgical software aids neurosurgeons in tumor removal by presenting the patient's brain network and surrounding fiber bundles, helping to evaluate the importance of these bundles and optimize surgical paths [3] - The software has received a Class II medical device registration in China and is already in use in multiple top-tier hospitals, with applications in over 10,000 neurosurgeries internationally [3] Group 4: Mental Health Treatment - The AI brain connectomics system shows potential in the neuro-regulation treatment of functional brain diseases, addressing clinical pain points in diagnosing and treating conditions like depression and anxiety [6][8] - The company is collaborating with hospitals to conduct larger-scale clinical trials for severe mental illnesses, while also establishing self-operated neuro-regulation clinics in major cities [9] Group 5: Market Potential - With over 1 billion people affected by neurological disorders globally, the increasing prevalence due to aging populations and lifestyle changes presents a significant market opportunity for innovative treatment solutions [9]